We are live on ! Find out more

Exelixis

EXEL

Market cap $13.9B

56.12 USD

-1.31

2.28%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

56.12

0.00

0%

1 day

-2.28%

5 days

-4.07%

1 month

9.33%

3 months

4.9%

6 months

34.42%

Year to date

28.77%

1 year

43.64%

5 years

177.55%

10 years

352.58%

About: Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Employees: 1,077

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 55.8%

Neutral 39.5%

Negative 4.7%

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

On Friday, the U.S. Food and Drug Administration (FDA) extended the review period for Exelixis Inc.‘s (NASDAQ:EXEL) new drug application (NDA) for zanzalintinib, in combination with atezolizumab, for metastatic colorectal cancer by three months.

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

U.S. FDA extends review of Exelixis' cancer drug

The ‌U.S. Food and Drug Administration has extended the review of Exelixis' experimental colorectal cancer drug combination by three ⁠months, the company said in a filing on Friday.

U.S. FDA extends review of Exelixis' cancer drug

Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Zacks Investment Research

Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Investors Business Daily

Cancer Stock Breaks Out To Highs; Key FDA Action On Watch

Cancer treatment name Exelixis is attempting to clear a flat base with a 57.57 pivot.

Cancer Stock Breaks Out To Highs; Key FDA Action On Watch

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Wells Fargo 21st Annual Healthcare Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 8:00 a.m. PT on Tuesday, September 8 in Boston. Citi 2026 Biopharma Back to School Conference: Exelixis is scheduled to present at 8:40 a.m. ET / 5:40 a.m. PT on Wednesday, September 9 in New York City. Morgan.

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data

Exelixis is downgraded from "Strong Buy" to "Hold" due to lowered 2026 revenue guidance and mixed clinical trial outcomes. Zanzalintinib + TECENTRIQ achieved overall survival benefit in mCRC, but missed the non-liver metastases subgroup endpoint; FDA PDUFA date set for December 3, 2026. Q2 2026 revenues rose to $628.7M, but future sales growth is uncertain and full-year guidance was cut to $2.500–$2.550B.

Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the Federal Circuit (Appeal No. 25-1236) has affirmed a key portion of the 2024 judgment of the U.S. District Court for the District of Delaware in Exelixis' favor. The appellate court upheld the District Court's decision that three patents covering.

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

See News Rankings

Price charts implemented using Lightweight Charts™